4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has 4SC's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VSC has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: VSC underperformed the German Biotechs industry which returned 2.8% over the past year.
Return vs Market: VSC underperformed the German Market which returned 3.9% over the past year.
Price Volatility Vs. Market
How volatile is 4SC's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StHow Does 4SC's (ETR:VSC) CEO Salary Compare to Peers?
3 months ago | Simply Wall StWe Think 4SC (ETR:VSC) Can Afford To Drive Business Growth
4 months ago | Simply Wall StDo Directors Own 4SC AG (ETR:VSC) Shares?
Is 4SC undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate VSC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate VSC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: VSC is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.
PE vs Market: VSC is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VSC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VSC is good value based on its PB Ratio (2.1x) compared to the DE Biotechs industry average (4.6x).
How is 4SC forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if VSC's forecast earnings growth is above the savings rate (0.2%).
Earnings vs Market: Insufficient data to determine if VSC's earnings are forecast to grow faster than the German market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: VSC's revenue (195.5% per year) is forecast to grow faster than the German market (6.1% per year).
High Growth Revenue: VSC's revenue (195.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VSC's Return on Equity is forecast to be high in 3 years time
How has 4SC performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VSC is currently unprofitable.
Growing Profit Margin: VSC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VSC is unprofitable, and losses have increased over the past 5 years at a rate of 13.6% per year.
Accelerating Growth: Unable to compare VSC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VSC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3.1%).
Return on Equity
High ROE: VSC has a negative Return on Equity (-48.9%), as it is currently unprofitable.
How is 4SC's financial position?
Financial Position Analysis
Short Term Liabilities: VSC's short term assets (€37.1M) exceed its short term liabilities (€3.5M).
Long Term Liabilities: VSC's short term assets (€37.1M) exceed its long term liabilities (€1.5M).
Debt to Equity History and Analysis
Debt Level: VSC is debt free.
Reducing Debt: VSC currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VSC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: VSC has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 11% each year.
What is 4SC current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VSC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VSC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VSC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VSC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VSC's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Jason Loveridge, B.Sc, Ph.D, FRSM, has been Corporate Advisor of Resonance Health Limited since June 30, 2017. Dr. Loveridge is a Founder of Invex. Dr. Loveridge has been Chairman of Management Board a ...
CEO Compensation Analysis
Compensation vs Market: Jason's total compensation ($USD799.86K) is above average for companies of similar size in the German market ($USD485.64K).
Compensation vs Earnings: Jason's compensation has increased whilst the company is unprofitable.
|Chairman of Management Board||4.08yrs||€679.00k||no data|
|Corporate Communications & Investor Relations Officer||no data||no data||no data|
|Chief Medical Officer||5.5yrs||no data||no data|
|Chief Development Officer||3.83yrs||no data||no data|
|Team Assistant||no data||no data||no data|
Experienced Management: VSC's management team is considered experienced (4.1 years average tenure).
|Member of Supervisory Board||15.17yrs||€28.00k||0.0054% |
|Chairman of Supervisory Board||6.08yrs||€48.00k||0.017% |
|Member of Supervisory Board||12.33yrs||€18.00k||no data|
|Member of Supervisory Board||8.17yrs||€26.00k||no data|
|Member of Supervisory Board||5.75yrs||€28.00k||0.0080% |
|Deputy Chairman of Supervisory Board||4.33yrs||€40.00k||no data|
|Member International Scientific Expert Panel||no data||no data||no data|
|Member International Scientific Expert Panel||no data||no data||no data|
Experienced Board: VSC's board of directors are considered experienced (7.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 30.1%.
4SC AG's company bio, employee growth, exchange listings and data sources
- Name: 4SC AG
- Ticker: VSC
- Exchange: XTRA
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €78.843m
- Shares outstanding: 45.97m
- Website: https://www.4sc.de
Number of Employees
- 4SC AG
- Fraunhoferstrasse 22
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|VSC||DB (Deutsche Boerse AG)||Yes||Common Bearer Shares||DE||EUR||Dec 2005|
|VSC||XTRA (XETRA Trading Platform)||Yes||Common Bearer Shares||DE||EUR||Dec 2005|
|0R6U||LSE (London Stock Exchange)||Yes||Common Bearer Shares||GB||EUR||Dec 2005|
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company’s products in clinical develo ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/19 21:08|
|End of Day Share Price||2020/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.